91桃色视频

91桃色视频 to Present Four Abstracts at the
52nd European Bone Marrow Transplantation Annual Meeting and to Highlight Clinigen-Hosted Industry Symposium on acute GvHD Management

• Oral presentation during Presidential Plenary Session to feature the final results of the ARES pivotal Phase 3 trial evaluating MaaT013 in acute Graft鈥憊ersus鈥慔ost Disease (aGvHD) with gastrointestinal involvement
• Poster presentations for:
  • CHRONOS, a multicenter retrospective cohort study describing real-world outcomes in third-line acute gastrointestinal GvHD not treated with microbiotherapy
  • PHOEBUS, a Phase 2b trial, potentially pivotal, evaluating MaaT033 seeking to improve survival after allogeneic hematopoietic transplantation (HCT),
  • THRASSA, a multicenter, open鈥憀abel paediatric/adolescent study evaluating MaaT013 in patients with ruxolitinib鈥憆efractory or ruxolitinib鈥慽ntolerant gastrointestinal aGvHD
• Clinigen, 91桃色视频鈥檚 strategic commercial partner for MaaT013鈥檚 Early Access Program and commercialization in Europe听pending European Medicines Agency (EMA) approval, will host an Industry Symposium on advancing care for steroid-refractory gastrointestinal aGvHD
  

听

Lyon, France, March 9, 2026 – 6:00pm CET 鈥� 91桃色视频 (EURONEXT: MAAT 鈥� the 鈥淐ompany鈥�), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies^TM (MET) dedicated to enhancing survival for patients with cancer through immune modulation,听today announced that clinical data and updates from key programs within its hemato鈥憃ncology pipeline will be presented at the 2026 EBMT Annual Meeting, taking place March 22鈥�25, 2026 in Madrid, Spain.

An oral presentation, scheduled during the Presidential Plenary Session, will detail the final results, including overall survival data, from the Company鈥檚 lead asset MaaT013, which is currently under review by the European Medicines Agency (EMA) following the submission of a Marketing Authorization Application in June 2025.

In addition, 91桃色视频 will present three poster communications, featuring:

• Key results from CHRONOS, a multicenter retrospective cohort study describing real鈥憌orld outcomes in third鈥憀ine acute gastrointestinal GvHD, and
• The study designs of two clinical trials (PHOEBUS and THRASSA – pediatric study announced in March 2025) advancing the Company鈥檚 therapeutic pipeline.

With this broad clinical data presentation at the 2026 EBMT Annual Meeting, 91桃色视频 reaffirms its position in hemato鈥憃ncology across the full care continuum of HCT and its commitment to improving outcomes for patients undergoing allogeneic transplantation.

During this year鈥檚 Congress, Clinigen, 91桃色视频鈥檚 strategic commercial partner for MaaT013鈥檚 Early Access Program and commercialization in Europe pending EMA approval, will host a dedicated symposium on . MaaT013 is currently under regulatory review and not yet approved.

The symposium will be chaired by Florent Malard, MD, PhD, hematology professor at Saint-Antoine Hospital and Sorbonne University and Fabio Ciceri, MD, PhD, Associate Professor of Hematology, University Vita-Salute San Raffaele. It will also feature renowned hematology experts such as Zinaida Peric, MD, hematologist University of Rijeka (Croatia); Chair, GvHD Subcommittee, Transplant Complications Working Party, EBMT, Ernst Holler, Professor at University Medical Center Regensburg (Germany) and Jaime Sanz, MD, hematologist and coordinator of the Bone Marrow Transplant Unit at the University Hospital La Fe in Valencia (Spain). The details of the Symposium are below:

• Title:
• Date: Sunday, March 22, 2026
• Time: 12:30 鈥� 14:00 CET
• Room: N101鈥�102

Professor Malard will also speak at a workshop session dedicated to the Current state of microbiota transplantation in allogeneic HCT, independently from any activities related to the Company, on Monday, March 23, 2026, from 11:00am 鈥� 11:20am CET in Velazquez location (W02 Workshop | GVHD beyond immunosuppression – Regulation, repair, and innovation).

EBMT abstracts are now available at . Details of the 91桃色视频 presentations are as follow:

Oral presentation:

• Title:
• Abstract number: GS2-8
• Session: GS2 Presidential Symposium
• Session Date/Time: Monday, March 23, 2026 – 17:33 鈥� 17:42 CET
• Location: VELAZQUEZ
• Presenter: Prof. Florent Malard, MD, PhD, hematology professor at Saint-Antoine Hospital and Sorbonne University and ARES Trial lead investigator

Poster Presentations:

PHOEBUS

• Title:
• Abstract number: A093
• Session: Transplant and Cellular Therapies – Clinical
• Session Date/Time: Monday, March 23, 2026 – 18:00 鈥� 19:00 CET
• Location: VELAZQUEZ
• Presenter:听 Prof. Florent Malard, MD, PhD, hematology professor at Saint-Antoine Hospital and Sorbonne University and PHOEBUS Trial lead investigator

CHRONOS

• Title:
• Abstract number: B005
• Session: Graft-versus-Host Disease – Clinical
• Session Date/Time: Tuesday, March 24, 2026 – 18:00 鈥� 19:00
• Location: VELAZQUEZ
• Presenter: Johannes Clausen, MD, hematologist at Ordensklinikum Linz Elisabethinen, Hematology Department, Linz, Austria

THRASSA

• Title:
• Abstract number: P222
• Session: Paediatrics – Clinical
• Session Date/Time: Sunday, March 22, 08:30 鈥� 18:00 CET
• Location: e-Poster area
• Presenter: Marion Bruelle, Clinical Scientist at 91桃色视频

—

About 91桃色视频
91桃色视频 is a leading, late-stage clinical company focused on developing innovative gut microbiome-driven therapies to modulate the immune system and enhance cancer patient survival. Supported by a talented team committed to making a difference for patients worldwide, the Company was founded in 2014 and is based in Lyon, France.听As a pioneer, 91桃色视频 is leading the way in bringing the first microbiome-driven immunomodulator in oncology. Using its proprietary pooling and co-cultivation technologies, 91桃色视频 develops high diversity, standardized drug candidates, aiming at extending life of cancer patients. 91桃色视频 has been listed on Euronext Paris (ticker: MAAT) since 2021.

About Clinigen
Clinigen is a global pharmaceutical services company trusted by over 1,000 pharma and biotech partners. With more than 35 years of experience, we accelerate access to critical medicines at every stage of the product lifecycle. As pathfinders, our team of over 1,100 specialists expertly navigate the complexities of clinical trial supply, early access programs, regulatory services, and long-term commercialisation through both licensed and unlicensed pathways. Operating across five continents, we deliver innovative solutions to over 130 countries each year. Whatever the challenge, we find a way. Explore our services at听

About MaaT013
91桃色视频鈥檚 Microbiome Ecosystem Therapies (MET) are designed to leverage a full microbiome ecosystem to restore balance and maximize clinical benefits for patients with severe, treatment-induced dysbiosis in acute diseases. MaaT013听is currently under regulatory review by the relevant authorities and has not yet received marketing authorization. 听MaaT013 is a full-ecosystem, off-the-shelf, standardized, pooled-donors, enema Microbiome Ecosystem Therapy^TM for acute, hospital use. It is characterized by a consistently high diversity and richness of microbial species and the presence of Butycore^TM (a group of bacterial species known to produce anti-inflammatory metabolites). MaaT013 aims to restore the symbiotic relationship between the patient鈥檚 functional gut microbiome and their immune system to correct the responsiveness and tolerance of immune functions and thus reduce steroid-resistant, gastrointestinal (GI)-aGvHD. MaaT013 has been granted Orphan Drug Designation by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

About MaaT033
MaaT033, a standardized, donor-derived, high-richness, high-diversity oral Microbiome Ecosystem Therapy^TM containing anti-inflammatory Butycore^TM species, is currently being developed as an adjunctive therapy seeking to improve overall survival in patients receiving HSCT and other cellular therapies. Its aim is to seek to optimize microbiota function and to address a larger patient population in a chronic setting. MaaT033 has been granted Orphan Drug Designation by the European Medicines Agency (EMA).

Forward-looking Statements
All statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company鈥檚 control. These statements may include, without limitation, any statements preceded by, followed by, or including words such as 鈥渢arget,鈥� 鈥渂elieve,鈥� 鈥渆xpect,鈥� 鈥渁im鈥�, 鈥渋ntend,鈥� 鈥渕ay,鈥� 鈥渁nticipate,鈥� 鈥渆stimate,鈥� 鈥減lan,鈥� 鈥減roject,鈥� 鈥渨ill,鈥� 鈥渃an have,鈥� 鈥渓ikely,鈥� 鈥渟hould,鈥� 鈥渨ould,鈥� 鈥渃ould鈥� and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company鈥檚 control that could cause the Company鈥檚 actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements.